

Clinical Trials Highlights



Lymphoma

Phase II Study of Anti-CD20 Antibody Therapy Plus Pembrolizumab (MK-3475) in Subjects with Relapsed Follicular and Diffuse Large B-Cell Lymphoma

Principal Investigator: Stephen D. Smith, MD
NCT03401853

Safety and Efficacy Study of Epcoritamab in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia

Principal Investigator: Mazyar Shadman, MD, MPH
NCT04623541

Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma

Principal Investigator: Ryan C. Lynch, MD
NCT04231877

Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma.

Principal Investigator: Ryan C. Lynch, MD
NCT03776864

Leukemia/MDS/MPN

Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients with Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome or High-Risk Myeloproliferative Neoplasm

Principal Investigator: Mary-Beth M. Percival, MD
NCT03737955

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

Principal Investigator: Anna B. Halpern, MD
NCT04551066

A Study of Subcutaneous Blinatumomab Administration in Acute Lymphoblastic Leukemia (ALL) Patients

Principal Investigator: Ryan D. Cassaday, MD
NCT04521231

Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) (ENHANCE)

Principal Investigator: Anna Halpern, MD
NCT04313881

Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

Principal Investigator: Anna Halpern, MD
NCT04282187

A Study of ALX148 With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)

Principal Investigator: Bart L. Scott, MD
NCT04417517

Multiple Myeloma

A Randomized Study of Dara Plus Len Versus Len Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

Principal Investigator: Andrew J. Cowan, MD
NCT0390193

A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM

Principal Investigator: Andrew J. Cowan, MD
NCT04184050

NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non Hodgkin Lymphoma & Combined With Daratumumab for Multiple Myeloma

Principal Investigator: Andrew J. Cowan, MD
NCT04136756

Blood and Marrow Transplant

CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease

Principal Investigator: Filippo B. Milano, MD, PhD
NCT04526288

A Study of Axatilimab at 3 Different Doses in Patients With Chronic Graft Versus Host Disease (cGVHD) (AGAVE-201)

Principal Investigator: Stephanie J. Lee, MD, MPH
NCT04710576

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Principal Investigator: Filippo B. Milano, MD, PhD
NCT04195633

Ustekinumab for the Prevention of Acute Graft Versus Host Disease After Unrelated Donor Hematopoietic Cell Transplant

Principal Investigator: Stephanie J. Lee, MD, MPH
NCT04572815

Cord Blood Transplant With OTS for the Treatment of HIV Positive Hematologic Cancers

Principal Investigator: Filippo B. Milano, MD, PhD
NCT04083170

211At-BC8-B10 and Donor Stem Cell Transplant in Treating Relapsed or Refractory AML, ALL, or Myelodysplastic Syndrome

Principal Investigator: Phuong T. Vo, MD
NCT03670966

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

Principal Investigator: Marie E. Bleakley, MD, PhD, MMSC
NCT03779854

Connect with our team

Hematology and Hematologic Malignancy

Phone: (206) 606-1260

Fax: (206) 606-1290

Email: pccheme@seattlecca.org

Blood and Marrow Transplant Program

Refer a patient or connect with a senior level physician

Phone: (800) 804-8824

Email: hutchdoc@seattlecca.org

Clinical Coordinator Pager: (206) 314-0807

Cellular Immunotherapy

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Principal Investigator: Mazyar Shadman, MD, MPH
NCT03277729

Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T cells (CART) in B-cell Lymphoma

Principal Investigator: Ajay K. Gopal
NCT04257578

An Open-Label, Phase 1/2 Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Principal Investigator: Mazyar Shadman
NCT03331198

Cellular Immunotherapy Program

Refer a patient or connect with our specialized immunotherapy team

Phone: (866) 268-6129

Email: immunotherapy@seattlecca.org
[SeattleCCA.org/referrals](https://seattlecca.org/referrals)

Clinical trials

View our current list of clinical trials

[SeattleCCA.org/clinical-trials](https://seattlecca.org/clinical-trials)

Long-Term Follow-Up Program

Phone: (206) 667-4415

Fax: (206) 667-5619
